Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Adv Drug Deliv Rev. 2012 Aug 17;64(13):1363–1384. doi: 10.1016/j.addr.2012.08.005

Figure 3.

Figure 3

(A) Nanoparticles with ligands specific for endothelial cell surface markers allow for binding and accumulation to tumor vasculature. (B) Once in the tumor tissue, nanoparticles with ligands specific for tumor cell markers can actively bind to tumor cells, enhancing accumulations and promoting receptor-mediated endocytosis. Figure taken from reference [69].